Amgen Defends Its Turf as Competition Looms for Anemia Drug
As a looming battle with Roche approaches, Amgen is preparing to defend its anemia franchise, now worth $7 billion a year, through pricing and lawsuits.
Medicare News Blog
A news blog on all things Medicare.
